Should You Buy GlaxoSmithKline plc, AstraZeneca plc & Hargreaves Lansdown plc Ahead Of The Results This Week?

Dave Sullivan digs deeper into prospects for GlaxoSmithKline plc (LON: GSK), AstraZeneca plc (LON: AZN) and Hargreaves Lansdown plc (LON: HL) ahead of their results this week.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

I don’t know about you, but I for one am glad to see the back of January. Despite my personal portfolio’s small-cap growth-oriented construction, I’ve been along for the ride on the turbulent market roller coaster.

That said, the volatility has, in my opinion opened some interesting opportunities. However, as we head into February investors will be updated with both interim and preliminary results from a lot of companies, which could well impact on the share price in either direction.

A quick glance at the 12-month chart shows all three shares under review comfortably outperforming the FTSE 100.

But once we close that chart to a month view, a slightly different picture emerges with only one company, GlaxoSmithKline (LSE: GSK) outperforming the blue-chip index.

Defying the bears?

I’ve been watching shares in pharma giant GlaxoSmithKline for a while now. As I’ve written before, I’ve been conscious of the level of dividend cover falling to less than 1 for the year to December 2015.

However, the market has been marking the shares higher of late, perhaps due to their perceived safe-haven appeal, perhaps due to the possibility that investors are beginning to believe the company’s prospects will improve as its business is reshaped following the deal with Novartis.

Currently, I’m still cautious and will wait for the results as analysts have been marking down their EPS estimates over the last one-month and three-months, albeit by only 1 penny per share, according to data from Stockopedia.

Back on the up?

On the other side of the coin, or brokers’ forecasts to be more precise, we’ve seen earnings estimates rise by around $22m at sector peer Astrazeneca (LSE: AZN). This puts the shares on a 12-month rolling forecast P/E of just under 16 times and the shares are set to yield in excess of 4%.

In addition, it’s pleasing to see that the level of dividend cover is beginning to rise too, with dividend cover expected to increase to 1.55 times for the year ending December 2015 – much safer than the less-than-one-times cover for the previous financial year.

As we can see, the shares have more or less tracked the index over the last month, which leaves me thinking that they’re in need of a catalyst to get them moving in the right direction. Whether this will arrive with the full-year results is yet to be seen.

Paying up for quality?

It’s hard to argue with the returns over the last 12 months delivered to shareholders in investment management firm Hargreaves Lansdown (LSE: HL). The shares have significantly outperformed the index and rightly so in my view.

As I’ve written before, it’s rare to see such quality in a mature blue-chip company. Indeed it’s the quality on offer here that you could argue justifies the eye-watering 32 times forecast earnings price tag that the shares attract.

Despite the quality here, investors may well see the shares hit by the postponement of the Lloyds Banking Group public share sale that was specifically mentioned by CEO Ian Gorham when the company updated the market back in October 2015. Indeed, broker forecasts have been sliding for some time now, and there’s room for some further downgrades should the market fall further. Despite this, the dividend is expected to grow again this year, giving a forecast yield of just under 3%

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Dave Sullivan has no position in any shares mentioned. The Motley Fool UK has recommended AstraZeneca, GlaxoSmithKline, and Hargreaves Lansdown. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Arrow symbol glowing amid black arrow symbols on black background.
Investing Articles

£5,000 of 9.2%-yielding Legal & General shares could make me £599 a month in passive income over time!

Legal and General shares remain a top passive income stock in my core portfolio holdings, with a 9.2% yield and…

Read more »

Investing Articles

With a 10.4% yield, P/E ratio of 9.9, and a P/B of 0.37, is this FTSE 100 stock a no-brainer buy for me?

Using a range of popular valuation measures, this FTSE 100 stock appears to offer tremendous value for money. So is…

Read more »

Three signposts pointing in different directions, with 'Buy' 'Sell' and 'Hold' on
Investing Articles

Down nearly 18% from its 52-week high, is the Lloyds share price now a screaming buy for me?

In recent weeks, the Lloyds share price has under-performed the wider market. Could this be the buying opportunity that I’m…

Read more »

Investing Articles

As BAE Systems’ share price drops 14% should I buy more?

FTSE 100 defence giant BAE Systems recently reiterated strong growth guidance, leaving its share price looking significantly undervalued to me.

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

After an 18% jump on its 2024 results, is it too late for me to consider buying this FTSE 100 hidden gem?

This FTSE 100 technology firm unveiled very strong 2024 results recently and a big share buyback, but is it too…

Read more »

Investing Articles

£5,000 invested in Rolls-Royce shares in 2023 would have made this much by now

Rolls-Royce shares have been one of the best-performing UK FTSE 100 investments over the last two years. But how much…

Read more »

Young Asian woman holding a cup of takeaway coffee and folders containing paperwork, on her way into the office
Investing Articles

£5,000 invested in Lloyds shares in 2023 would be worth this much now

Lloyds shares and other banking stocks have thrived in 2024, but has it been a good investment for shareholders who…

Read more »

Burst your bubble thumbtack and balloon background
Investing Articles

Why are investors blowing a raspberry at this FTSE 250 stock?

After a successful IPO, the share price of this FTSE 250 stock's fallen. Our writer looks at the reasons and…

Read more »